47° Sunny

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
- Contact Us
- Subscribe
News
Sports
Features
Classifieds
Obituaries
Subscribe
E-Edition
Community Choice

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

35.10 -2.34 (-6.25%)

Streaming Delayed Price Updated: 3:03 PM EST, Nov 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Structure Therapeutics Inc. - American Depositary Shares

< Previous 1 2 3 4 Next >

12 Health Care Stocks Moving In Friday's After-Market Session ↗

November 07, 2025

Via Benzinga

This Under-the-Radar Healthcare Stock Could Soar in 2026 ↗

September 12, 2025

We should know a lot more by year-end.

Via The Motley Fool

Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound ↗

August 07, 2025

Via Stocktwits

Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations

August 07, 2025

Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the...

Via MarketMinute

Topics Economy

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors ↗

August 07, 2025

Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates.

Via Benzinga

Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge. ↗

August 07, 2025

An analyst called the unexpected flop a "once-in-a-blue-moon" occasion for Eli Lilly's dominant weight-loss franchise.

Via Investor's Business Daily

There are notable gap-ups and gap-downs in today's session. ↗

April 17, 2025

Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps.

Via Chartmill

uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday ↗

April 17, 2025

Via Benzinga

Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullish ↗

April 15, 2025

Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates.

Via Stocktwits

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today ↗

April 14, 2025

Pfizer bows, but is not entirely out of the GLP-1 race.

Via The Motley Fool

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? ↗

April 14, 2025

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition.

Via Benzinga

The State of Weight Loss Drugs ↗

March 10, 2025

Via The Motley Fool

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. ↗

March 03, 2025

This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1.

Via Investor's Business Daily

Why Structure Therapeutics Stock Was Stumbling This Week ↗

February 14, 2025

Via The Motley Fool

AI Pharma: 2 Paths to AI-Powered Drug Investment

January 28, 2025

AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.

Via MarketBeat

Topics Artificial Intelligence

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst ↗

January 06, 2025

JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.

Via Benzinga

Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche ↗

December 18, 2024

Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments.

Via Investor's Business Daily

Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

December 18, 2024

Via Benzinga

Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf? ↗

December 16, 2024

The weight-loss drugs space continues to heat up. Here's the latest news from the segment.

Via Investor's Business Daily

Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry? ↗

November 22, 2024

Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints.

Via Investor's Business Daily

Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition ↗

October 23, 2024

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 16, 2024

Via Benzinga

Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade ↗

October 14, 2024

The analyst is closely watching MariTide, a potential monthly injection to treat obesity.

Via Investor's Business Daily

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer ↗

October 04, 2024

Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.

Via Investor's Business Daily

Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday ↗

September 30, 2024

Via Benzinga

BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO ↗

September 26, 2024

The company is working on a drug that mimics apelin, which is released following exercise.

Via Investor's Business Daily

Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review ↗

September 13, 2024

The major indexes reclaimed key levels and many leaders flashed buy signals.

Via Investor's Business Daily

The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race ↗

August 29, 2024

The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots.

Via Investor's Business Daily

3 Promising Biotech Stocks for the Long-Term: August 2024 ↗

August 13, 2024

Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.

Via InvestorPlace

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard Times

Services

Contact Us
Subscription Services
Promote Your Event
Site Forms
Search

ricentral.com
187 Main Street
Wakefield, RI 02879
Phone: 401-789-9744
Email: news@ricentral.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

Headline News about Structure Therapeutics Inc. - American Depositary Shares

Sections

Services